CJC-1295 & GHRP-2 Blend (10mg) – Research Peptide

CJC-1295 & GHRP-2 Blend (10mg) is an experimental peptide formulation designed for laboratory research into growth-hormone signalling, pituitary function and the interaction between growth-hormone-releasing hormone (GHRH) and growth-hormone-secretagogue pathways.

The referenced formulation contains 5mg of CJC-1295 No DAC and 5mg of GHRP-2, providing a total peptide content of 10mg. The product is supplied as a lyophilised powder with a stated purity of >99%.

CJC-1295 No DAC and GHRP-2 are experimental peptides associated with different signalling pathways involved in the regulation of growth-hormone release. CJC-1295 No DAC is studied as a modified GHRH-related peptide, while GHRP-2 is a synthetic growth-hormone-releasing peptide associated with the growth-hormone secretagogue receptor (GHS-R1a).

The scientific interest in combining these compounds comes from research suggesting that GHRH-related and GHS receptor pathways can influence pituitary growth-hormone secretion through complementary mechanisms.

Studies of GHRH and GHRP-2 have reported enhanced GH responses under certain experimental conditions. However, findings from individual peptides or related combinations should not automatically be interpreted as evidence for the exact 10mg formulation.

---

What Is the CJC-1295 & GHRP-2 Blend?

The CJC-1295 & GHRP-2 Blend combines two synthetic research peptides associated with the study of the growth-hormone axis.

CJC-1295 No DAC is commonly associated with Modified GRF 1-29 and is investigated in relation to GHRH receptor signalling. GHRH is a naturally occurring hypothalamic hormone involved in stimulating growth-hormone secretion from pituitary somatotroph cells.

GHRP-2, also known as Growth Hormone-Releasing Peptide-2 or Pralmorelin, is a synthetic hexapeptide investigated as a growth-hormone secretagogue. Research has associated GHRP-2 with the growth-hormone secretagogue receptor (GHS-R1a), which is also known as the ghrelin receptor.

The two compounds therefore provide researchers with an experimental model for examining two related but distinct signalling routes involved in GH regulation.

---

CJC-1295 No DAC – Research Profile

CJC-1295 No DAC is commonly described in research contexts as Modified GRF 1-29 or Mod GRF 1-29. It is related structurally to the active region of growth-hormone-releasing hormone.

GHRH binds to receptors located on pituitary somatotroph cells and forms part of the physiological mechanism regulating growth-hormone secretion. Research involving GHRH analogues therefore focuses on receptor activity, pituitary signalling and GH release.

It is important to distinguish the No DAC form from CJC-1295 preparations containing a Drug Affinity Complex (DAC). These forms have different pharmacological characteristics and should not be treated as interchangeable research materials.

Research on CJC-1295 has demonstrated that the compound can influence GH and IGF-1 concentrations in human experimental settings, particularly in studies of the longer-acting CJC-1295 form. These findings provide useful background for understanding CJC-1295-related research but should not be automatically transferred to every No-DAC formulation.

---

GHRP-2 – Growth-Hormone Secretagogue Research

GHRP-2 is a synthetic hexapeptide belonging to the growth-hormone-releasing peptide family. It is also known as Pralmorelin.

Research has associated GHRP-2 with the GHS-R1a receptor, a receptor involved in the biological actions of ghrelin and several synthetic growth-hormone secretagogues.

Unlike GHRH analogues, GHRP-2 represents a separate secretagogue pathway. Research involving GHRP-2 has examined its effects on pituitary GH secretion, hypothalamic signalling and other endocrine responses.

Studies have also demonstrated that GHRP-2 can affect appetite-related signalling. Human research has reported increased food intake following acute GHRP-2 administration, illustrating why the compound should be viewed as an experimental endocrine-active peptide rather than simply as a GH-specific research reagent.

---

CJC-1295 & GHRP-2 Blend Product Highlights

• Product name: CJC-1295 & GHRP-2 Blend
• Total peptide content: 10mg
• CJC-1295 No DAC: 5mg
• GHRP-2: 5mg
• Blend ratio: 1:1 by stated mass
• Form: Lyophilised powder
• Stated purity: >99%
• Research classification: Experimental peptide blend
• Primary research area: Growth-hormone and pituitary signalling
• Research pathways: GHRH-related and GHS-R1a signalling
• Intended purpose: Laboratory and research use

---

CJC-1295 & GHRP-2 Chemical Profile

Property	CJC-1295 No DAC	GHRP-2
Alternative designation	Mod GRF 1-29	Pralmorelin
Quantity in blend	5mg	5mg
Total blend quantity	10mg
Blend ratio	1:1 by stated mass
General classification	GHRH-related peptide	Growth-hormone secretagogue
Research-associated receptor	GHRH receptor	GHS-R1a
Physical form	Lyophilised powder
Stated purity	>99%

---

How the Growth-Hormone Axis Works

The growth-hormone axis is a complex endocrine system involving the hypothalamus, pituitary gland and peripheral tissues.

Growth-hormone secretion is regulated by several interacting signals. GHRH promotes GH secretion from pituitary somatotrophs, while somatostatin provides an inhibitory signal. Ghrelin and synthetic growth-hormone secretagogues can also influence GH release through the GHS receptor pathway.

This complex regulation is one reason researchers investigate different peptide classes individually and in combination. Studying separate receptor pathways can provide insight into the mechanisms governing pulsatile GH secretion.

---

Different Signalling Pathways

Peptide	Research-associated pathway	Primary research interest
CJC-1295 No DAC	GHRH receptor	GHRH-related pituitary signalling
GHRP-2	GHS-R1a / ghrelin receptor	Growth-hormone-secretagogue signalling

Research literature supports the concept that GHRH and GHRP compounds can influence GH release through distinct receptor systems.

---

Why Combine CJC-1295 and GHRP-2?

The main scientific rationale for combining CJC-1295 and GHRP-2 is the possibility of studying complementary growth-hormone signalling pathways.

CJC-1295 No DAC is investigated in relation to the GHRH receptor, whereas GHRP-2 is associated with the GHS-R1a pathway. These pathways are distinct but converge on the regulation of pituitary growth-hormone secretion.

Experimental studies involving GHRH and GHRP-2 have reported enhanced GH secretion when the two signalling systems are stimulated together. In one in-vitro study, combined GHRH and GHRP-2 altered GH release and expression of several signalling-related genes in ovine pituitary somatotrophs.

These findings provide a scientific basis for investigating combinations of GHRH-related peptides and GHRP compounds. However, evidence involving native GHRH or other GHRH analogues is not necessarily equivalent to evidence for this specific CJC-1295 No DAC and GHRP-2 formulation.

---

Research Interest in GH Secretion

Growth hormone is released in a pulsatile pattern rather than at a constant rate. The frequency and magnitude of these pulses vary according to factors such as age, sex, sleep, nutritional status and metabolic state.

Researchers therefore examine not only overall GH concentrations but also pulse frequency, pulse amplitude, baseline concentrations and downstream markers such as IGF-1.

Research involving CJC-1295 has shown that certain CJC-1295 preparations can increase GH and IGF-1 concentrations while preserving aspects of pulsatile secretion in healthy adults.

These findings are relevant to the broader scientific context of CJC-1295 research, but they should not be interpreted as clinical evidence for the specific CJC-1295 No DAC and GHRP-2 blend.

---

CJC-1295 No DAC vs CJC-1295 With DAC

The terminology surrounding CJC-1295 can be confusing because different formulations are discussed under the same general name.

Feature	CJC-1295 No DAC / Mod GRF 1-29	CJC-1295 With DAC
DAC component	Absent	Present
General research classification	Modified GHRH-related peptide	Longer-acting GHRH analogue
Research focus	GHRH receptor signalling	Extended GH-axis pharmacology
Pharmacokinetic characteristics	Different from DAC-containing preparations	Designed to extend circulating exposure

Published human studies of CJC-1295 have primarily examined the long-acting form and therefore should not automatically be used to characterise a product specifically identified as CJC-1295 No DAC.

---

GHRP-2 and GHS-R1a Research

The growth-hormone secretagogue receptor, or GHS-R1a, is a G-protein-coupled receptor associated with ghrelin signalling and the actions of several synthetic GH secretagogues.

Research into GHS-R1a has examined its role in growth-hormone secretion as well as appetite, energy balance and metabolic signalling.

GHRP-2 is therefore of interest beyond its effects on pituitary GH release. Experimental research has demonstrated that its physiological actions can involve multiple endocrine pathways.

---

GHRP-2 and Appetite Research

GHRP-2 is structurally and functionally related to the broader family of growth-hormone secretagogues. Because the GHS-R1a receptor is involved in both GH regulation and appetite-related signalling, GHRP-2 research can extend beyond the pituitary gland.

A controlled human study reported that acute GHRP-2 administration increased food intake in healthy men compared with saline. This finding highlights the broader physiological activity associated with GHS-R1a stimulation.

Accordingly, research involving GHRP-2 should consider the possibility of effects outside the growth-hormone pathway when interpreting experimental results.

---

Growth Hormone and IGF-1 Research

Growth hormone is closely associated with the growth hormone–insulin-like growth factor 1 (GH–IGF-1) axis.

GH can stimulate IGF-1 production, particularly in the liver. IGF-1 then acts on receptors in numerous tissues and contributes to several physiological processes related to growth and metabolism.

For this reason, experimental studies of GH secretagogues and GHRH analogues may monitor both GH and IGF-1 rather than evaluating GH concentrations alone.

Human research involving CJC-1295 has demonstrated increases in circulating GH and IGF-1 under experimental conditions.

However, changes in GH or IGF-1 concentrations should not be equated automatically with therapeutic benefit, improved athletic performance, fat loss or other consumer-facing outcomes.

---

Potential Research Applications

The CJC-1295 & GHRP-2 Blend may be relevant to controlled laboratory investigations involving:

• Pituitary research: Investigation of somatotroph responses to peptide signalling.
• Growth-hormone research: Study of mechanisms regulating GH release.
• GHRH receptor research: Investigation of signalling associated with GHRH-related peptides.
• GHS-R1a research: Study of the growth-hormone secretagogue receptor.
• Peptide pharmacology: Comparison of different classes of endocrine-active peptides.
• Hormonal signalling: Investigation of interactions between GHRH and secretagogue pathways.
• GH–IGF-1 research: Study of relationships between growth hormone and downstream IGF-1 signalling.
• Receptor interaction studies: Examination of responses produced by simultaneous pathway activation.
• Analytical research: Development and validation of methods for peptide identification and characterisation.

---

Understanding the 10mg Formulation

The 10mg designation represents the total quantity of peptide material in the referenced product.

• 5mg CJC-1295 No DAC
• 5mg GHRP-2

This produces a stated 1:1 blend by mass.

The 10mg quantity is a product specification and should not be interpreted as a recommended human dose, treatment regimen or clinical administration instruction.

---

Lyophilised Peptide Preparation

The CJC-1295 & GHRP-2 Blend is supplied as a lyophilised powder.

Lyophilisation, also known as freeze-drying, is commonly used for peptide research materials. The process removes water from a frozen preparation under controlled conditions and produces a dry material suitable for subsequent laboratory handling and analytical characterisation.

Researchers should use appropriate laboratory procedures and consult batch-specific documentation when handling experimental peptide materials.

---

Analytical Quality and Purity

Analytical characterisation is an important part of peptide research. Researchers should verify the identity and purity of experimental materials before incorporating them into controlled laboratory studies.

Common analytical techniques include:

• High-performance liquid chromatography (HPLC): Used to assess chromatographic purity.
• Mass spectrometry: Used to support molecular identity and molecular-weight confirmation.
• Certificate of Analysis: Provides batch-specific analytical information where available.
• Lot traceability: Helps researchers maintain consistency between experimental batches.

The referenced Core Peptides listing specifies a stated purity of >99% for this 10mg blend.

---

Research Evidence for CJC-1295

Published research has investigated CJC-1295 as a GHRH analogue and examined its effects on GH and IGF-1 concentrations.

In a randomised, placebo-controlled study of healthy adults, the long-acting CJC-1295 preparation produced dose-dependent increases in mean plasma GH and IGF-1 concentrations. The study investigated pharmacokinetics, pharmacodynamics and safety under controlled experimental conditions.

A separate study found that CJC-1295 increased trough and mean GH secretion while preserving the pulsatile character of GH secretion in the study population.

These studies are useful for understanding the biological research surrounding CJC-1295, but they involved specific CJC-1295 preparations and should not be assumed to establish the characteristics of every CJC-1295 product, particularly No-DAC formulations.

---

Research Evidence for GHRP-2

GHRP-2 has been extensively studied as a synthetic growth-hormone secretagogue.

Experimental studies have demonstrated that GHRP-2 can stimulate GH secretion through secretagogue-related signalling. Research has also examined interactions between GHRP-2 and GHRH in pituitary models.

GHRP-2 has also been investigated in human subjects, including research examining its effects on appetite and food intake.

These findings demonstrate that GHRP-2 is an endocrine-active research compound with biological activity extending beyond a simple isolated GH response.

---

Research Interest in Combined GHRH and GHRP Signalling

One of the principal reasons researchers investigate GHRH analogues and GHRPs together is the possibility that the two pathways can interact.

GHRH and GHRP-2 have been studied in pituitary models, with combined treatment producing changes in GH secretion and expression of genes associated with pituitary signalling.

Earlier research has also described distinct receptor systems for GHRH and synthetic GH secretagogues, supporting the concept that multiple upstream pathways can participate in the regulation of pituitary GH secretion.

For this reason, the CJC-1295 and GHRP-2 combination is scientifically interesting as an experimental model of interacting GH-secretory pathways.

---

Limitations of Current Research

Despite substantial research interest, important limitations should be considered when evaluating CJC-1295 and GHRP-2 blends.

• Exact formulation evidence: Studies of the individual compounds or other combinations do not establish the properties of this precise 5mg/5mg formulation.
• Different CJC-1295 forms: Research involving DAC-containing CJC-1295 should not automatically be applied to CJC-1295 No DAC.
• Limited clinical evidence for intended consumer uses: Experimental endocrine activity does not establish efficacy for body composition, performance or other non-approved uses.
• Potential endocrine effects: Manipulating the GH–IGF-1 axis can affect multiple physiological systems.
• Metabolic uncertainty: Changes in GH signalling may influence glucose and lipid metabolism.
• Appetite-related activity: GHRP-2 has demonstrated appetite-related effects in human research.
• Long-term safety: Long-term safety of unapproved peptide blends remains insufficiently established.

A 2026 review of performance-enhancing peptides highlights the limited regulatory evidence and uncertainties surrounding unapproved GH-axis peptides, including CJC-1295 without DAC and GHRP-2, and notes reported endocrine and metabolic adverse effects associated with this broader class of compounds.

---

CJC-1295 & GHRP-2 Blend – Research Summary

CJC-1295 & GHRP-2 Blend (10mg) is an experimental peptide formulation containing equal quantities of CJC-1295 No DAC and GHRP-2. The referenced product contains 5mg of each peptide for a total of 10mg and is supplied as a lyophilised powder with a stated purity above 99%.

CJC-1295 No DAC is studied in relation to GHRH-associated signalling, while GHRP-2 is investigated as a growth-hormone secretagogue associated with GHS-R1a. The different signalling routes provide a scientific rationale for examining the peptides together in controlled laboratory research.

Research involving GHRH and GHRP-2 has demonstrated that stimulation of these pathways can influence pituitary GH secretion and may produce enhanced responses under certain experimental conditions.

However, evidence concerning related peptides or different CJC-1295 preparations should not be presented as direct evidence for this exact 10mg blend. The formulation should therefore be regarded as an experimental research material, rather than a clinically established treatment.

---

Frequently Asked Questions About CJC-1295 & GHRP-2 Blend (10mg)

What is the CJC-1295 & GHRP-2 Blend?

It is an experimental two-peptide formulation containing 5mg CJC-1295 No DAC and 5mg GHRP-2, for a total peptide content of 10mg.

What does the 10mg quantity mean?

The 10mg specification refers to the total amount of peptide material in the formulation. It consists of 5mg of CJC-1295 No DAC and 5mg of GHRP-2.

What is CJC-1295 No DAC?

CJC-1295 No DAC is commonly associated with Modified GRF 1-29 and is studied as a GHRH-related peptide involved in research into pituitary growth-hormone signalling.

What is GHRP-2?

GHRP-2, also known as Pralmorelin, is a synthetic hexapeptide studied as a growth-hormone secretagogue and associated with the GHS-R1a receptor.

Why are CJC-1295 and GHRP-2 combined?

The two peptides are associated with different signalling pathways involved in growth-hormone regulation. Their combination provides an experimental model for studying interactions between GHRH-related and growth-hormone-secretagogue signalling.

What is the ratio of the two peptides?

The referenced formulation contains a stated 1:1 ratio by mass, with 5mg of each peptide.

Is CJC-1295 No DAC the same as CJC-1295 with DAC?

No. CJC-1295 No DAC and DAC-containing CJC-1295 preparations have different structural and pharmacological characteristics. Researchers should verify the precise formulation used in any scientific study.

Is the 10mg quantity a recommended human dose?

No. The 10mg figure describes the amount of research material supplied and is not a human dosage recommendation.

What form is the product supplied in?

The referenced product is supplied as a lyophilised powder.

What is the stated purity?

The referenced Core Peptides listing states a purity of >99%.

Does the blend have proven synergistic effects?

Research involving GHRH and GHRP-2 supports investigation of complementary signalling pathways, and some studies have reported enhanced GH responses when the pathways are stimulated together. However, these findings do not constitute direct proof of a specific synergistic effect from this exact commercial blend.

Is this product an approved medicine?

No. The product is presented as an experimental research peptide blend and should not be represented as an approved medicinal product or established treatment.

Can research on CJC-1295 be applied directly to this blend?

Not automatically. Published studies may involve different CJC-1295 formulations, particularly DAC-containing preparations. Researchers should confirm the precise peptide form before comparing results.

---

Research-Use Disclaimer

CJC-1295 & GHRP-2 Blend (10mg) is intended for laboratory and research use only. It is not a medicine, dietary supplement, food product or approved therapeutic treatment.

The information provided in this product description is intended for scientific and educational purposes. It summarises research associated with the individual peptide components and their respective signalling pathways and should not be interpreted as evidence that this blend can diagnose, treat, cure or prevent any disease or medical condition.

The available evidence concerning the exact formulation is limited. Findings from studies involving individual compounds, native GHRH, other GHRH analogues or different CJC-1295 preparations should not automatically be attributed to this specific 5mg/5mg blend.

This description does not provide instructions for human administration, dosing, injection, reconstitution for human use or self-experimentation. Researchers should consult relevant scientific literature, batch-specific analytical documentation, institutional procedures and applicable laws and regulations when working with experimental peptide materials.